BACKGROUND: Expression of individual oncogenes may predict outcome in patients with metastatic colorectal cancer (CRC). We studied the oncogene profile in the tumors of patients with CRC and assessed their value as predictors of liver metastases. METHODS: The oncoproteins c-myc, c-erbB-2/neu (c-neu), PCNA and p53, were measured by immunohistochemistry in sections of metastasizing human CRC (n = 34) and their liver secondaries as well as in sections of nonmetastasizing human CRC (n = 25). RESULTS: The metastasizing primary CRC expressed proliferating-cell nuclear antigen (PCNA), c-neu, and c-myc at significantly higher levels than the nonmetastasizing primary cancer, p53 was also overexpressed in the metastatic group compared with the nonmetastasizing CRC, but this difference was not significant. The frequency of expression of all these markers was similar in the metastasizing primary CRC and the liver secondaries from the same patients. There was no correlation between the expression of the individual markers and histological grade, DNA ploidy, and subsequent local recurrence and lung metastasis and survival. However, when both groups were assessed together, positive expression of c-myc was more likely to occur in poorly differentiated tumors, whereas PCNA expression increased with more advanced Dukes stages. CONCLUSION: These results suggest that the overexpression of c-myc, c-neu, PCNA, and p53 may occur in CRC that are likely to metastasis to the liver.
BACKGROUND: Expression of individual oncogenes may predict outcome in patients with metastatic colorectal cancer (CRC). We studied the oncogene profile in the tumors of patients with CRC and assessed their value as predictors of liver metastases. METHODS: The oncoproteins c-myc, c-erbB-2/neu (c-neu), PCNA and p53, were measured by immunohistochemistry in sections of metastasizing human CRC (n = 34) and their liver secondaries as well as in sections of nonmetastasizing human CRC (n = 25). RESULTS: The metastasizing primary CRC expressed proliferating-cell nuclear antigen (PCNA), c-neu, and c-myc at significantly higher levels than the nonmetastasizing primary cancer, p53 was also overexpressed in the metastatic group compared with the nonmetastasizing CRC, but this difference was not significant. The frequency of expression of all these markers was similar in the metastasizing primary CRC and the liver secondaries from the same patients. There was no correlation between the expression of the individual markers and histological grade, DNA ploidy, and subsequent local recurrence and lung metastasis and survival. However, when both groups were assessed together, positive expression of c-myc was more likely to occur in poorly differentiated tumors, whereas PCNA expression increased with more advanced Dukes stages. CONCLUSION: These results suggest that the overexpression of c-myc, c-neu, PCNA, and p53 may occur in CRC that are likely to metastasis to the liver.
Authors: J Jen; H Kim; S Piantadosi; Z F Liu; R C Levitt; P Sistonen; K W Kinzler; B Vogelstein; S R Hamilton Journal: N Engl J Med Date: 1994-07-28 Impact factor: 91.245
Authors: Dong Il Park; Mun Su Kang; Suk Joong Oh; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Won Kon Han; Hungdai Kim; Seung Ho Ryu; Antonia R Sepulveda Journal: Int J Colorectal Dis Date: 2006-09-01 Impact factor: 2.571
Authors: H H J Backus; C J Van Groeningen; W Vos; D F Dukers; E Bloemena; D Wouters; H M Pinedo; G J Peters Journal: J Clin Pathol Date: 2002-03 Impact factor: 3.411
Authors: Anand G Menon; Rob A E M Tollenaar; Cornelis J H van de Velde; Hein Putter; Connie M Janssen-van Rhijn; Rob Keijzer; Gert Jan Fleuren; Peter J K Kuppen Journal: Clin Exp Metastasis Date: 2004 Impact factor: 5.150
Authors: Kuo Ping Chiu; Pramila Ariyaratne; Han Xu; Adrian Tan; Patrick Ng; Edison Tak-Bun Liu; Yijun Ruan; Chia-Lin Wei; Wing-Kin Ken Sung Journal: BMC Cancer Date: 2007-06-26 Impact factor: 4.430